Tag Archives: health

Substances of Human Origin (or SoHO): the New EU Regulation

Legal news, , , ,

PURPOSE OF THE NEW REGULATION. On June 13, 2024, the European Parliament and the Council adopted a new regulation on the substances of human origin (so-called SoHO), repealing Directives 2002/98/EC and 2004/23/EC. The new regulation:

  • was necessary because previous directives only partially managed to harmonize member states’ legislation on cells, tissues and blood; also, a new definition of SoHO was needed;
  • introduces mechanisms to grant continuity and resilience of SoHO supplies and to facilitate EU cross border exchanges and access to SoHO;
  • enhances safety of donors and recipients (included the offspring born from medical assisted procreation).

WHAT IS A ‘SOHO’? A SoHO is now defined as “any substance collected from the human body, whether or not it contains cells and whether or not those cells are alive, including SoHO preparations resulting from the processing of the above-mentioned substance”. The definition has been expanded to include breast milk and gut microbiota, as well as blood preparations different from those used for transfusions. Any future SoHO will be automatically included in the regulation. The regulation also defines SoHO preparation as a SoHO subjected to processing, with a specific clinical indication, intended for human application on a recipient or for distribution.

WHO DEALS WITH SOHO? The regulation also defines which will be the main actors in the organizational chain from SoHO donation to application. Specifically:

  • A SoHO entity is a legal entity established in the EU that carries out SoHO-related activities (e.g. collection, processing, control, storage, release, distribution, import, export, application on human beings,  clinical studies and outcomes recording on SoHO preparations)
  • A SoHO establishment is a SoHo entity that carries out one of the following SoHO-related activities: A) both processing and storage; B) release; C) import; D) export;
  • Competent authorities for SoHO are appointed by each member state and 1) maintain SoHO entities’ registry, 2) deal with authorization process for SoHO establishments and SoHO preparations 3) carry out inspections and evaluate plans for monitoring clinical outcomes.

WHEN?  The regulation will be enforceable by mid-2027.

TAKEAWAYS. Apparently, it is science-friendly as the definition of SoHO will be broader and more flexible than before. Also, in view of its structure, there is hope that it will succeed in ensuring more uniformity and granting an enhanced minimum level of safety across EU.

Processing of personal and health data through apps and online platforms aimed at connecting HCPs and patients: the new digest of the Italian DPA

Legal news, , , , , , , , , , , , , , , , , , , , , ,

On March 2024, the Italian Data Protection Authority (“Italian DPA”) has issued a new digest (“Digest”) relating to the processing of personal data, whether or not concerning health data pursuant to section 9 of the GDPR, carried out through the utilization of platforms, accessible through apps or web pages (“Platforms”), that aim to facilitate connection between healthcare professionals (“HCPs”) and patients.

The use of such Platforms poses high risks to the protection and security of patients’ personal data, and in particular health-related data, given that the latter are subject to an enhanced protection regime set forth by section 9 of the GDPR. 

The Digest seeks to summarize the applicable data protection rules that may be followed, and defines the roles of the parties, as well as the legal bases, applicable to (i) the processing of personal data of the users by Platform’s owners; (ii) the processing of HCP’s personal data by Platform’s owners; and (iii) the processing of health data of the patients by the Platform’s owner and by the HCPs.

Additional guidance is provided as to:

  • The necessity for the Platform’s owner to carry out (and periodically update) a data protection impact assessment (DPIA) pursuant to section 35 GDPR, since the use of Platforms determine a “high risk” processing of personal data, as such kind of treatment automatically meets the criteria issued by the European Data Protection Board for the identification of the list of data processing that may be deemed subject to the duty to perform a DPIA;
  • Which information notices should be provided, by who and to whom, as well as the contents that such information notices should have in each case, according to sections 13 and 14 GDPR;
  • The specific rules applicable to cross-border data transfers and data transfer to third countries.

Lastly, the Digest includes a list of the most common measures that are taken by the data controllers to ensure an appropriate level of technical and organizational measures to meet the GDPR requirements, such as encryption, verification of the qualification of the HCPs that seek to enroll within the Platform; strengthened authentication systems, monitoring systems aimed at preventing unauthorized access or loss of data.

The Digest should be very welcomed by the Platform’s owners, as it now gives a reliable and complete legal frame that may be followed in order to set up a Platform in a way which is compliant with the GDPR principles.

The Italian Government Fund for the Governance of Medical Devices

Legal news, , , , , , , ,

With Ministerial Decree dated December 29, 2023, the Italian Ministry of Health has established criteria and methods for feeding the fund dedicated to the governance of medical devices, the so-called “Fondo per il governo dei dispositivi medici” (Fund for medical devices governance, “Fund”).

Key Features

  • Annual payment obligation.  Companies manufacturing or distributing medical devices, large medical equipment and in vitro diagnostic medical devices must pay a sum equal to 0.75% of the company’s previous year turnover from the sale of such devices to the National Health Service, net of VAT.
  • Annual Declaration Requirement.  Companies must submit an annual statement to the Ministry of Health regarding:
    • The estimated amount of 0.75% of the above-mentioned turnover.
    • The company’s previous year turnover to the National Health Service, net of VAT;
  • Use of the Fund. The Fund will be used for various activities related to Health Technology Assessment and governance of medical devices (including the management of the National Price Observatory, the vigilance system and the market surveillance system).
  • Deadlines and next steps. The first deadline for compliance with the fund regulations is set for December 31, 2024.

Companies are currently assessing whether the Fund can be challenged in court with arguments that may be similar to those raised in the so called “payback” litigation, which will see its day in Court (namely, the Italian Constitutional Court) on May 22, 2024.

Implementation of the “231” Compliance Model in the Pharma Industry: New Guidelines issued by the Italian Association of Pharmaceutical Companies

Legal news, , , , , , , , , , , , , , , ,

On September 5, 2023, the Italian Association of Pharmaceutical Companies (“Farmindustria” – https://www.farmindustria.it/) has issued guidelines to design an organizational model pursuant to the Legislative Decree 231/2001 in the pharmaceutical sector (“Guidelines”).

In particular, the Guidelines, by taking into account the main peculiarities of the pharma industry, seek to identify the typical activities that are most at risk for the commission of criminal offences, and provide detailed guidance about the main policies and preventive actions that should be carried out by companies in order to prevent their commission.

As expected, the highest risks concern relationships with public officials, which may lead to crimes such as corruption or fraud against the State, with significant advantages for pharma companies.

The Guidelines seek to drive the attention of companies involved in the pharma sector on the risks that are latent in the following areas:

  • Relationships with healthcare professionals (“HCP”) and healthcare organizations (“HCO”): compliance programs should regulate activities of the key account managers and their bonuses, sponsorship of congresses, grants and donations to HCOs, gifts to HCPs, as well as other sponsorship or advertisement activities;
  • Relationships with Public Authorities: many interactions with public officials may entail corruptions risks, such as, e.g., obtainment of Market Authorizations, price reimbursement negotiations with the Italian drug regulatory agency (AIFA – https://www.aifa.gov.it/), management of site visits and inspections, participation and execution of public tenders for the supply of drugs to HCOs;
  • Relationships with private entities: relationships with suppliers providing services in the context of clinical studies, pharmacies, patient advocacy organizations, patients and “expert patients”, or management of patient support programs also need to be regulated.

The Guidelines also offer a complete set of policies and other preventive remedies that may be sufficient to prevent the envisaged criminal risks.

The Guidelines are a useful tool for pharma companies and no similar initiatives have been taken by other associations with regard to different industries and sectors. The Guidelines also constitute a benchmark for best practices that will be difficult to ignore.

Do you need help in designing or updating your company’s “231” compliance model? Do not hesitate to reach out!

G7 Health Summit Closed Today in Milan

Events, , , , , , , , , ,

On November 5 and 6 the G7 Ministerial Meeting on Health was held in Milan. The meeting had an ambitious agenda, ranging from the impact of climate change on people’s health to antibiotic resistance.

According to the Italian Ministry of Health, hosting the summit on the occasion of the 2017 Italian G7 presidency, the meeting innovated in the way matters have been examined and discussed, by using a so called Delphi method based on the opinions of the world’s leading experts.

A number of satellite events have also taken place across the city, including a conference organized by police forces to address the cross-border fight against “pharmaceutical crime” in all its forms, identifying the critical factors and common responses. The conference focused on the strategies and international collaborations needed to crack down on counterfeit pharmaceutical products, as well as the import and on-line sales of unauthorized products.

Another satellite event focused on the employment of new technologies in the healthcare sector, with particular emphasis on sustainability. Antibiotic resistance has also been a key item on the agenda. Italy is among the countries in the world where deaths linked to antibiotic resistance are higher.

Italian authorities did not conceal that one of the hidden goals of the summit was for them to lobby for the relocation of the European Medicines Agency- EMA headquarters to Milan. The political battle among candidate cities is about to get more intense, as a decision is expected to be adopted before the end of November.

More information on the agenda and materials of the summit can be found here: http://www.g7italy.it/en.

The last event of our HEALTH INNOVATION ACADEMY is coming up!

Uncategorized, , , ,

On May 21, 2015 our HEALTH INNOVATION ACADEMY series will hold its last event. Join us to hear speakers on the topic of networks for innovation at Via Francesco Sforza 28, Milano (Aula Milani) followed by drinks.

As always, the event is organized in cooperation with the hospital IRCSS Cà Granda – Ospedale Maggiore Policlinico di Milano and with Politecnico di Milano – e-Health LAB – Informatica BioMedica e Sanità Digitale

To find out more about the May 21 program or about HEALTH INNOVATION ACADEMY’s past events, click here: http://healthinnovationacademy.weebly.com/reti-dellinnovazione.html